Get started
Author

Julia Yemelyanenko

Observed names: Julia Yemelyanenko-Lyalenko, Yemelyanenko, J.
ORCID: 0000-0001-9697-2039
Observed ORCID: 0000-0001-9697-2039
OpenAlex ID: A5083409381
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022 · Daniel Zingg, Jinhyuk Bhin, et al. · Nature · 121
PDF
Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disorders
2020 · Karlijn van Loon, Julia Yemelyanenko-Lyalenko, et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 33
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
2023 · Jinhyuk Bhin, Julia Yemelyanenko, et al. · The Journal of Experimental Medicine · 26
PDF
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system
2020 · Sjoerd Klarenbeek, Chris W. Doornebal, et al. · OncoImmunology · 17
PDF
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022 · Daniel Zingg, Jinhyuk Bhin, et al. · Nature · 16
PDF
C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2025 · Julia Yemelyanenko, Jinhyuk Bhin, et al. · Cancer Research · 2
The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
2025 · Daniel Zingg, Chi-Chuan Lin, et al. · Cancer Research · 2
Abstract LB_B04: Deciphering FGFR3-TACC3 oncogenic fusions
2023 · Julia Yemelyanenko, Jinhyuk Bhin, et al. · Molecular Cancer Therapeutics · 1
Supplementary Data S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Table S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S9 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S7 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S8 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S4 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Table S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S4 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S6 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S6 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Methods S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Supplementary Figure S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2026 · Julia Yemelyanenko, Jinhyuk Bhin, et al.
Works count: 48
Citation count: 218
H-index: 5
I10-index: 5
Year
Topic
Type